Pharma Funding Roundup: QuantX Biosciences, Pandorum Technologies Complete Series B Financing Rounds
QuantX will deploy Series B proceeds toward IND-enabling advancement of oral STAT6 and IL-17 inhibitors in immunology/inflammation and continued discovery expansion on its computational platform.
Pharmaceutical programs operate under a unique combination of long development cycles, strict regulatory oversight, and high commercial stakes. Execution spans R&D, regulatory affairs, quality, supply ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results